Immunoclin (Immunoclin) EPS (Basic) : $-0.30 (TTM As of Oct. 2014)

View and export this data going back to 2012. Start your Free Trial

What is Immunoclin EPS (Basic)?

Immunoclin's basic earnings per share (Basic EPS) for the three months ended in Oct. 2014 was $-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Oct. 2014 was $-0.30.

Immunoclin's EPS (Diluted) for the three months ended in Oct. 2014 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2014 was $-0.30.

Immunoclin's EPS without NRI for the three months ended in Oct. 2014 was $-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Oct. 2014 was -0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Immunoclin EPS (Basic) Historical Data

The historical data trend for Immunoclin's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin EPS (Basic) Chart

Immunoclin Annual Data

Trend

Feb12

Jan13

Jan14

EPS (Basic)

-0.02

-0.01

-1.21

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
EPS (Basic)	Get a 7-Day Free Trial									-0.01	-0.01	-0.03	-0.04	-0.22

Immunoclin EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Immunoclin's Basic EPS for the fiscal year that ended in Jan. 2014 is calculated as

Basic EPS (A: Jan. 2014 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.98	-	0)	/	10.775
	=	-1.20

Immunoclin's Basic EPS for the quarter that ended in Oct. 2014 is calculated as

Basic EPS (Q: Oct. 2014 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.117	-	0)	/	27.896
	=	-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30

Immunoclin (GREY:IMCL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Immunoclin EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Immunoclin's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210

Website

http://www.immunoclin.com

Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines